Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder

@article{McGough2005DexmethylphenidateEC,
  title={Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder},
  author={J. McGough and C. Pataki and Robert L Suddath},
  journal={Expert Review of Neurotherapeutics},
  year={2005},
  volume={5},
  pages={437 - 441}
}
Medications for attention deficit hyperactivity disorder (ADHD) currently represent the ninth largest segment of the CNS market by sales, with US$2.4 billion spent annually on this condition and 40% annual growth. Stimulant medications remain the most effective ADHD therapies and provide robust improvement in ADHD symptoms in both youth and adults. Current prescribing practices favor extended release preparations due to increased convenience, compliance and tolerability with once-daily dosing… Expand
20 Citations
Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.
  • 17
  • PDF
Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth.
  • S. Faraone, E. Giefer
  • Psychology, Medicine
  • Journal of the American Academy of Child and Adolescent Psychiatry
  • 2007
  • 46
...
1
2
...

References

SHOWING 1-10 OF 45 REFERENCES
New drugs for the treatment of attention-deficit/hyperactivity disorder
  • 13
Neurobehavioral effects of racemic threo-methylphenidate and its d and l enantiomers in rats
  • 34
Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.
  • 827
  • PDF
...
1
2
3
4
5
...